Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06328647 · ClinicalTrials.gov registry record · NA

Quantra Point-of-Care Hemostasis Monitoring

A NA study of Bleeding and Hemostatic Disorder, sponsored by The Cleveland Clinic.

Recruiting
Registry status
NA
Development phase
666
Enrollment target
1
Study location

NCT06328647: Recruiting NA study of Bleeding and Hemostatic Disorder, sponsored by The Cleveland Clinic.

NCT06328647 is a NA study of Bleeding and Hemostatic Disorder that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 666 participants, below the 1,456-participant average among 23 other Bleeding trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06328647, a NA study of Bleeding and Hemostatic Disorder, is actively recruiting participants, sponsored by The Cleveland Clinic.

RECRUITING
Registry status
NA
Development phase
666 participants
Enrollment target
1
Study location

Study Summary

The investigators will test the hypothesis that utilization of a blood and blood component transfusion algorithm guided by the POC Quantra QPlus System in patients undergoing complex cardiac surgery will reduce RBC, plasma, cryoprecipitate, and platelet transfusion during surgery and the first 12 postoperative hours, compared to standard of care (central laboratory transfusion monitoring at the primary anesthesia provider's discretion).

Primary Outcome

The total number of blood and blood component transfusions (including RBC, plasma, cryoprecipitate, and platelets) during and after cardiac surgery until 12 hours after ICU arrival.

Interventions

  • DEVICE POC Quantra QPlus System
  • OTHER Routine care

Study Locations (1)

Ohio

  • Cleveland Clinic Foundation - Cleveland

Trial Details

FieldValue
Enrollment Target 666 participants
Start Date 2024-10-03
Est. Completion 2026-12-31
Phase NA
The Cleveland Clinic

688 total trials

What NCT06328647 shows while recruiting

NCT06328647 is an interventional study that assigns participants to a tested intervention. The registered 666 participants enrollment target is mid-sized for trials with a published cap, below the 1,456-participant average among 23 other Bleeding trials with a reported enrollment target (54% lower).

The record links to 2 conditions, with Bleeding appearing as the primary indexed condition, and to 2 interventions - of which POC Quantra QPlus System is the first listed.

NCT06328647 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT06328647 about?

NCT06328647 is a clinical study titled "Quantra Point-of-Care Hemostasis Monitoring". The investigators will test the hypothesis that utilization of a blood and blood component transfusion algorithm guided by the POC Quantra QPlus System in patients undergoing complex cardiac surgery will reduce RBC, plasma, cryoprecipitate, and platelet transfusion during surgery and the first 12 po...

What is the current status of trial NCT06328647?

This trial is currently recruiting. It is a NA study. The enrollment target is 666 participants. The study started on 2024-10-03. Estimated completion is 2026-12-31.

What conditions does trial NCT06328647 study?

This clinical trial studies the following conditions: Bleeding, Hemostatic Disorder.

What interventions are being tested in trial NCT06328647?

The interventions under investigation include: POC Quantra QPlus System (DEVICE), Routine care (OTHER).

Who is sponsoring clinical trial NCT06328647?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06328647 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bleeding

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06328647's enrollment target sits among peer trials

666 6th of 23 higher than 18 of 23 other Bleeding trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bleeding trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06981078 · 666 participants · Phase 2

    A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

  • NCT04064060 · 665 participants · Phase 3

    A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

  • NCT04155034 · 668 participants · Phase 3

    S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

  • NCT04179981 · 668 participants · NA

    Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06328647, the US trial registry maintained by the National Library of Medicine. NCT06328647 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.